Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2016

View Archived Issues

GnHR antagonist SKI-2670 well tolerated, suppresses hormones in phase I trial

Sirenas enters drug discovery collaboration with Calibr

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Two mutations at the same anticodon stem pair may cause different myopathic phenotypes

Hookipa Biotech presents data on CMV vaccine candidate

PSMA ligand [99mTc]MIP-1427 improves diagnostics in osseous metastasized prostate cancer

Argonaut Therapeutics raises funds to develop cancer drugs

Advanced Proteome Therapeutics acquires option to antibody candidates from University of Toronto

Pfizer wins grant from Bill & Melinda Gates Foundation for GBS vaccine trial

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Merck & Co. patents TrK-A inhibitors

Shionogi discloses ACC2 inhibitors

FDA grants accelerated approval for Lartruvo in soft tissue sarcoma

Takeda Pharmaceutical describes ACC1 inhibitors

Fujifilm Kyowa Kirin Biologics reports phase III results for adalimumab biosimilar FKB-327

Spotlight Innovation obtains exclusive worldwide license for STL-182

ICGEB and Sun Pharma collaborate on new tetravalent dengue vaccine

Pivotal phase III study of letermovir meets primary endpoint

Texas A&M University develops pateamine A analogues

Incyte presents LSD1 inhibitors

MHRA accepts XOMA's proposal for phase II study of XOMA-358 in congenital hyperinsulinism

Cerulean collaborates with Novartis to develop nanoparticle-drug conjugate product candidates

Rare SHANK3 mutation may be a risk factor for ASD and schizophrenia

Applied Genetic Technologies files IND for second achromatopsia therapeutic candidate

Australian NHMRC funds research in chronic lung diseases

Perlara forms drug discovery collaboration with Novartis

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...